Sustained Release T3 Therapy

[jimh111]

Review of the current state of development of sustained release T3 frontiersin.org/articles/10... .

[helvella Administrator Thyroid UK]

Note that Rudolf Hoermann, colleague of diogenes, was one of the reviewers.

Unless I missed it, I couldn't see a single reference to diogenes and co.

Still, interesting. Despite ending up pretty much implying that no, you can't have T3 until we have developed new products, no matter that your quality of life might improve.

[jimh111 in reply to helvella]

I must admit I haven't read the paper yet! I'm tied up with other work at home. I'm also working on some notes on how TSH affects deidinase which I will put on my website. Although many of us need T3 I feel it's more important to understand why we need it and how to eliminate this need rather than just finding better forms of T3. Better forms of T3 are welcome but we still need to understand why so many of us need more T3 than when we were healthy.

[diogenes Remembering in reply to jimh111]

I agree with that. If new forms of T3 are ade available then first, there will be a long period of safety and effectiveness study and second, patents will be issued to the companies with deep pockets who can conduct such longterm studies and then charge the earth for the product, safe behind patent walls. Also, I believe that there is a kind of slow release product already in existence - its called NDT or DTE. Re Bianco et al's omission of our work. This is quite deliberate. Bianco wants the understanding of thyroid action to come from his animal studies and sexy genetics. And thereby gaining his kudos. It must be galling to find out that one can get much closer to the answer by studying human response directly. So we must be ignored at all costs, because otherwise his fox is shot.

[jimh111 in reply to diogenes]

I tend to agree. As I mentioned I'm in favour of the more radical approach of discovering why some patients need substantial doses of T3. If we can solve this problem we are left with patients such as those with DIO2 polymorphisms who need smaller doses. In this latter group concerns about the short half-life of T3 are limited and they can always take it two or three times daily, or simply take a mix of levothyroxine and NDT.

[diogenes Remembering]

Oh and incidentally Rudolf Hoermann thought the content was good, but the conceptualisation lacked a clear direction.